Trending...
- Adostics & Genmega Announce the Introduction of A-POD
- Deliverance Service Coming to Hagerstown, MD
- LIB and Nidec Rejoin Forces for Giant TH-0098 Temperature Humidity Test Chamber
Primetime Life Sciences Progresses PTLS-181 for Treating Depression.
GERMANTOWN, Md. - Marylandian -- Primetime Life Sciences, LLC, a Maryland based pharmaceutical company focused on discovery and development of new and smart treatments, announced today that the company has successfully met the Phase I grant milestones, and has been awarded Phase II funding of $2.63 million from a Fast Track Small Business Innovation Research (SBIR) grant from the National Institute of Mental Health (NIMH). The SBIR program supports scientific excellence and technological innovation by encouraging small businesses to engage in translation research and bring innovative treatments.
The grant will support the development of the Company's lead compound, PTLS-181, for an innovative treatment of depression. Depression is a severe medical condition that affects millions of people with significant individual suffering and places an enormous socioeconomic burden for society.
More on Marylandian
Dr. Janak Padia, President and CEO of Primetime Life Sciences, stated, "We had put forward very aggressive Phase I milestones to provide a compelling rationale for PTLS-181 to initiate IND-enabling studies. We have successfully met these milestones. We are excited to progress PTLS-181 through IND-enabling studies and develop an efficacious treatment for depression."
NOTES TO EDITORS
About Primetime Life Sciences, LLC
Primetime Life Sciences (www.primetimelifesci.com) is a Maryland-based discovery and development company focusing on small molecule drugs. Our mission is to expedite the discovery and development of new and smart treatments by using a multi-disciplinary, highly collaborative, "bench-to-bedside" approach. The Company has developed a mutual prodrug platform using "Metformin Linker Kit" to improve pharmacokinetic and safety profiles of known drugs. The Company pipeline includes CNS, cancer, and parasitic therapeutics. For more information, please contact Dr. Janak Padia, Email: jpadia@primetimelifesci.com
http://www.primetimelifesci.com
The grant will support the development of the Company's lead compound, PTLS-181, for an innovative treatment of depression. Depression is a severe medical condition that affects millions of people with significant individual suffering and places an enormous socioeconomic burden for society.
More on Marylandian
- Third Annual African American Cultural Expo and Children's Book Fair Comes to Waldorf, MD
- Psychedelics for Vets? CCHR Cites History of Exploitation and Failed Science
- GreenPal Empowers Lawn Care Pros Leveraging AI, Surpasses 5 Million Transactions
- Santa Monica Businesses Push Back on Bus Stop Relocation That Threatens Access and Safety
- The Blue Luna Encourages Local Schools to Take Steps to Enhance Safety for Students and Staff
Dr. Janak Padia, President and CEO of Primetime Life Sciences, stated, "We had put forward very aggressive Phase I milestones to provide a compelling rationale for PTLS-181 to initiate IND-enabling studies. We have successfully met these milestones. We are excited to progress PTLS-181 through IND-enabling studies and develop an efficacious treatment for depression."
NOTES TO EDITORS
About Primetime Life Sciences, LLC
Primetime Life Sciences (www.primetimelifesci.com) is a Maryland-based discovery and development company focusing on small molecule drugs. Our mission is to expedite the discovery and development of new and smart treatments by using a multi-disciplinary, highly collaborative, "bench-to-bedside" approach. The Company has developed a mutual prodrug platform using "Metformin Linker Kit" to improve pharmacokinetic and safety profiles of known drugs. The Company pipeline includes CNS, cancer, and parasitic therapeutics. For more information, please contact Dr. Janak Padia, Email: jpadia@primetimelifesci.com
http://www.primetimelifesci.com
Contact
Primetime Life Sciences, LLC
Dr. Janak Padia, Email: jpadia@primetimelifesci.com
***@primetimelifesci.com
Primetime Life Sciences, LLC
Dr. Janak Padia, Email: jpadia@primetimelifesci.com
***@primetimelifesci.com
Source: Primetime Life Sciences, LLC
0 Comments
Latest on Marylandian
- Smart Resnse Unveils Smart Resnse(SRMS) Token-Powered AI Orchestration Platform to Revolutionize Multi-Billion Dollar Market
- Josh and Heidi Follow Up the Much Anticipated and Successful Launch of the "Spreading the Good BUZZ" Podcast with a Personal Request
- Local Filmmaker Brings Folklore and Film to Her Own Backyard in Silver Spring
- Revolutionary Blockchain Platform Okh Finance Announces Okh Finance(OKKH) Token Launch to Transform Global Asset Leasing Market
- Cover Girl Finalist Teisha Mechetti Questions Legitimacy of Inked Originals Competition, Demands Transparency
- Easton & Easton, LLP Files Suit Against The Dwelling Place Anaheim & Vineyard USA Over Abuse Allegations
- AI Visibility: The Key to Beating Google's AI Overviews and Regaining Traffic
- Stuck Doing Math or Figuring Out Life's Numbers? Calculator.now Makes It Stupidly Simple
- Colbert Packaging Announces WBENC Recognition
- DivX Empowers Media Enthusiasts with Free Expert Guides for Advanced MP4 Management
- Assent Expands Executive Team to Accelerate Global Growth & Innovation
- The World's Largest Green Economic Revolution Emerges as Nature, Tech, and Finance Converge
- Vinnetwork Unveils Decentralized AI Platform with Vinnetwork(VIN) Token to Challenge Tech Giants' Data Monopoly
- Centennial Flyers to Become Colorado's First Launch Customer for All-Electric B23 Energic Aircraft
- Pyro Marketing Opens New Digital Marketing Company to Power Growth for Fitness and Ecommerce Brands
- Dr. John Salerno of Salerno Wellness Introduces Their New Full Body Capsule for Advanced LED Light Therapy Patient Treatments
- $14M Expansion Deal with Famed David Lloyd Highlights Rebrand of Sports, Entertainment and Gaming Innovation by AI Driven, Online Fan Engagement Co
- Heartfelt Dreams Foundation Launches Campaign to Build CHD Hospital
- Radarsign Tackles Intersection Safety with Launch of Grid-Free Solar LED Stop Sign
- Miami Real Estate Agent Drastically Increases Interest In Homes